Amal Therapeutics Is A Swiss Biotechnology Company Focused On Developing Therapeutic Cancer Vaccinesthe Company Aims To Improve Cancer Treatment By Utilizing Its Kisimaaplatformwhich Is A Self Adjuvanting Protein Based Technology Designed To Stimulate Strong Immune Responsesthis Platform Combines Multiple Antigens Into A Single Chimeric Fusion Proteinallowing For Targeted Immune Activation Against Tumors One Of The Key Candidates In Development Is Atp128A Therapeutic Vaccine For Metastatic Colorectal Canceramal Therapeutics Prioritizes The Discovery And Development Of Vaccines That Create Immunological Memory To Prevent Cancer Recurrencethe Company Has Been Integrated Into Boehringer Ingelheim S Framework Since Its Acquisition In 2019Enhancing Its Capabilities In Cancer Immunologythrough Its Innovative Approachamal Therapeutics Addresses Challenges In Existing Immunotherapies By Improving Antigen Presentation And T Cell Activation
